No timeline for new late-stage prostate cancer treatment in Manitoba
September of last year, Health Canada gave a new prostate cancer treatment approval for patients with advanced metastatic cases.
It's called PLUVICTO (lutetium (177lu) vipivotide tetraxetan injection) which uses a radioactive particle to attack a certain type of cancer protein. But doctors say there are hurdles ahead for eligible patients to access the treatment, as its approval is just step one.
Prostate cancer is one of the most commonly diagnosed cancers in men. In 80 per cent of cases, the cancer cells have a surface protein called prostate-specific membrane antigen or PSMA. PSMA is the biomarker or target for PLUVICTO.
"I know that our nuclear medical physicians are extremely aware of this,” said Dr. Piotr Czaykowski, a medical oncologist at CancerCare Manitoba. “We have regular conversations with them about this. We know they're keen to try and implement this as soon as it’s something we can implement."
Czaykowski told CTV News this type of technology is already used in the province for a rare type of cancer called neuroendocrine tumour but getting PLUVICTO out to late-stage prostate cancer patients through the public system will take more time.
"Right now where this sits, is there are negotiations underway to establish a price and once that's in place then we have the opportunity to start trying to provide this," he said.
A provincial spokesperson tells CTV News, PLUVICTO has also received a positive recommendation from the Canadian Agency for Drugs and Technologies in Health (CADTH) but it still needs to undergo national negotiations through the panCanadian Pharmaceutical Alliance.
“Only after those negotiations are completed and an agreement is in place with the manufacturer, will Manitoba list the product in the oncology drug formulary,” reads the written statement.
Although it’s not available publicly, Canadians can choose to pay out of pocket for the treatment. At a private clinic in Burnaby, B.C., two patients received PLUVICTO treatments this week.
"The way we describe this is we see what we treat and we treat what we can see," said Dr. Philip Cohen, a nuclear medicine specialist and the medical director at INITIO Medical.
He said the price for the compound, whether being bought by the government or a patient, is $27,000 a dose.
"What I am hopeful for is, as more compounds will make it through the approval process, the cost will plummet and hopefully will become more affordable," said Cohen.
While optimistic for what nuclear treatments might be able to accomplish in the cancer realm, he points out another major issue that may make accessing this type of treatment difficult in Canada. A Positron Emission Tomography or PET scan is required to screen patients.
"There's probably an adequate number in Quebec but outside Quebec there's real limitations to access to pet scanners,” he said.
According to Shared Health there is only one PET scanner in Manitoba at Health Sciences Centre.
Czaykowski says while PLUVICTO is not a home run or a cure, it will be well worth offering to eligible late-stage prostate cancer patients.
"In the studies that have been done, and there was a large trial where half the patients got this therapy and the other half didn't, those who got the therapy lived about five months longer," he explained.
Adding, once there’s the science to support it, there is the potential for the agent to be used earlier during the course of treatment.
CTVNews.ca Top Stories
What to know about avian influenza in dairy cows and the risk to humans
Why is H5N1, or bird flu, a concern, how does it spread, and is there a vaccine? Here are the answers to some frequently asked questions about avian influenza.
'I was scared': Ontario man's car repossessed after missing two repair loan payments
An Ontario man who took out a loan to pay for auto repairs said his car was repossessed after he missed two payments.
opinion The special relationship between King Charles and the Princess of Wales
Royal commentator Afua Hagan writes that when King Charles recently admitted Catherine to the Order of the Companions of Honour, it not only made history, but it reinforced the strong bond between the King and his beloved daughter-in-law.
Man convicted of involuntary manslaughter in father's drowning, told police he was baptizing him
A Massachusetts man who told police he was exorcising a demon and performing a baptism when he shoved his father's head under water multiple times has been convicted of involuntary manslaughter in his death.
New Norad commander calls Canada's defence policy update 'very encouraging'
American troops will be spending more time training in the Far North, the new commander of Norad says, a strategy that fits 'hand-in-glove' with Canada's renewed focus on Arctic defence.
$70M Lotto Max winners kept prize a secret from family for 2 months
During a special winner celebration near their hometown, Doug and Enid shared the story of how they discovered they were holding a Lotto Max ticket worth $70 million and how they kept this huge secret for so long.
Are Canadians getting sick from expired food?
A new survey by Dalhousie University's Agri-Food Analytics Lab asked Canadians about their food consumption habits amid rising prices.
Documents reveal Ottawa's efforts to get Loblaw, Walmart on board with grocery code
It was evident to the federal government as early as last fall that Loblaw and Walmart might be holdouts to the grocery code of conduct, jeopardizing the project's success.
Hubble Space Telescope marks 34 years with new portrait of a 'cosmic dumbbell'
The Hubble Space Telescope has captured a stunning new image of the glowing gas ejected from a dying star, which in this case happens to resemble a 'cosmic dumbbell.'